Terns Pharmaceuticals(TERN) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Terns Pharmaceuticals Reports Third Quarter 2024 Financial Results and Corporate Updates Interim data from initial dose escalation cohorts of Phase 1 CARDINAL trial evaluating TERN-701 (allosteric BCR-ABL tyrosine kinase inhibitor) in chronic myeloid leukemia (CML) expected in early December 2024 Plans to initiate Phase 2 clinical trial for TERN-601 in obesity in early 2Q25 with initial 12-week data expected in 2H25 Cash, cash equivalents and marketable securities of $372.8 million, including $ ...